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Direct In Vivo Measurement of Human Cerebral GABA
Concentration Using MEGA-Editing at 7 Tesla
Melissa Terpstra, Kamil Ugurbil, and Rolf Gruetter*
Spectral editing of the GABA spin system is hampered by co-
editing of macromolecule (MM) coherences. To reduce contam-
ination arising from MMs in spectra edited for GABA, the high-
est field strength currently available for human experimentation
(7 Tesla) and MEGA-based editing were used. Despite judicious
choice of experimental parameters, MM contamination was
found to arise from field drifts. When the MM contribution was
accounted for, [GABA]  0.75  0.14 mol/g (mean  SD, N 
16) relative to 8 mol/g creatine (Cr), whereas without account-
ing for the MM signal [GABA*]  0.88  0.23 mol/g (mean 
SD, N  16). Incorporating the direct experimental assessment
of MM contamination to the edited GABA signal substantially
reduced the variance of the measurement, resulting in concen-
trations that were in excellent agreement with previous 13C
labeling experiments. Magn Reson Med 47:1009–1012, 2002.
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GABA (-aminobutyric acid (NH2-
CH2-
CH2-
CH2-CO2H))
is the major inhibitory neurotransmitter in the human
brain. 1H NMR spectroscopy has been used to detect hu-
man GABA levels in vivo (1,2) and to provide insight
regarding the action of antiepileptic medications (3,4). The
detection of the GABA resonance is complicated by over-
lap with resonances from other metabolites, including cre-
atine (Cr) and macromolecules (MMs). To extract the small
GABA signal from underneath the strong Cr singlet at
3.0 ppm, investigators have typically used homonuclear
editing based on the 7 Hz J coupling between the -CH2
resonance at 1.9 ppm and the -CH2 resonance at 3.0 ppm
(3). Editing pulses incorporated into point-resolved spec-
troscopy (PRESS) (5) have also been utilized to detect the
GABA resonance at 3.0 ppm (2) and to study the effects of
antiepileptic medications (6). Multiple quantum filtering
schemes have also been proposed (7–9).
However, editing of the -CH2 GABA resonance near
3.0 ppm is complicated by coediting of MM coherences
near 3.0 ppm which couple to a resonance at 1.7 ppm with
a similar homonuclear J coupling constant (10). Due to the
finite bandwidth of the editing pulse designed to invert the
-CH2 GABA resonance at 1.9 ppm, the MM resonance at
1.7 ppm is inadvertently excited, leading to significant
MM coherence generation (3,10). Single quantum editing
has been utilized in conjunction with a numerically opti-
mized editing pulse (1) to improve the selectivity of the
editing pulse. In addition, MM contamination is often
assessed by mathematical deconvolution (1). Alterna-
tively, Henry et al. (11) were the first to attempt MM
contamination-free GABA editing by applying the selec-
tive editing pulse symmetrically about the J-coupled MM
resonance at 1.7 ppm in the two steps of the editing
scheme. Their work highlights the importance of precise
and accurate setting of the editing pulse offset, and the
vulnerability of all prior methods to offset errors.
The primary goal of this work was to optimize editing
selectivity, and thus minimize MM contamination by: 1)
implementing symmetric pulsing (11) within the MEGA-
PRESS editing technique (2), and 2) performing experi-
ments at 7T, the highest magnetic field currently available
for human experimentation. The high magnetic field pro-
vided the additional benefits of improved sensitivity and a
greater frequency separation between Cr and GABA (12).
METHODS
Fourteen normal volunteers (six males and eight females,
average age 30 years), two of whom were studied twice,
gave informed consent for this study, which was con-
ducted according to procedures approved by the Institu-
tional Review Board and the U.S. Food and Drug Admin-
istration (FDA IDE #G980). All experiments were per-
formed with a 7T, 90-cm bore magnet (Magnex, Oxford,
UK) interfaced to a Varian INOVA spectrometer (Varian,
Palo Alto, CA) and head gradients (Magnex). Radiofre-
quency (RF) excitation was accomplished with a surface
1H quadrature transceiver (13) adapted to tune to
297 MHz. Subjects were positioned supine inside the mag-
net with the RF transceiver subjacent to their occipital
lobe. The protocol for each volunteer began with localizer
multislice rapid acquisition with relaxation enhancement
(RARE) images (TR  4.0 s, TE  23 ms, echo train
length  8, 256  128 matrix, two averages, 2-mm slice
thickness, five slices) for selection of a cubic volume of
interest (3  3  3 cm3) centered on the midsagittal plane
in the occipital lobe. Shimming of all first- and second-
order coils was achieved using a fast automatic shimming
technique with echo-planar signal trains using mapping
along projections, FAST(EST)MAP (14), resulting in water
linewidths of 10–17 Hz. Following adjustment of the spec-
trometer frequency, edited spectra were acquired as de-
scribed below.
Selective double-banded pulses incorporated into
MEGA-PRESS (fig. 2B of Ref. 2) accommodated simulta-
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neous localization, water suppression, and editing of the
-CH2 resonance of GABA at 3.0 ppm. Instead of applying
the editing lobe of the selective RF pulse symmetric about
water (at 7.54 ppm) during alternate scans (2), the editing
lobe was applied symmetric about the MM resonance at
1.7 ppm in order to reduce MM contamination (11). In
summary, the selective double-banded pulse was applied
at 4.7 and 1.9 ppm alternating with 4.7 and 1.5 ppm.
Additional water suppression using variable power with
optimized relaxation delays (VAPOR) and outer volume
suppression, OVS, (15) were adapted for the human
7 Tesla system (12) and incorporated prior to MEGA-
PRESS. Use of a high magnetic field (7 Tesla) rendered the
editing pulse more selective because of the increased fre-
quency separation between GABA and MM at higher field.
Each acquisition was stored separately in memory and
individually phase-corrected based on the NAA signal. All
processing was performed using spectrometer built-in soft-
ware.
To assess contributions of the MM spin system to the
edited signal, a “metabolite-nulled” spectrum (2,10) was
collected to complement each edited spectrum. A compar-
ison of metabolite-nulled spectra to spectra acquired with-
out nulling revealed that the MM resonance at 0.9 ppm,
which did not overlap with metabolites, was not fully
relaxed. Therefore, assuming identical T1 relaxation, the
MM resonance near 3.0 ppm in the metabolite-nulled
spectrum was not fully relaxed, thus underestimating MM
contamination. The area under the MM resonance at
0.9 ppm was determined both with and without preinver-
sion, providing a correction factor for T1 relaxation, which
was 1.29  0.05 (mean  SD, N  9), consistent with an
MM T1 of approximately 0.5 s. Changing this correction
factor by 30% affected the resulting GABA concentration
by less than 5%. In all cases, the TR was 4.5 s.
The GABA concentration was calculated from the signal
intensities according to:
[GABA] 
3(IGABA*  IMM)
2ICrEffE
Cr [1]
where [GABA] represents the GABA concentration after
subtracting the measured MM contamination. GABA con-
centration calculated without accounting for MM contam-
ination (IMM  0) is referred to as [GABA*]. ICr represents
the area under the Cr methyl peak at 3.03 ppm obtained by
peak fitting using spectrometer software. IGABA* represents
the area under the edited peak at 3.0 ppm, which was fit as
two singlets, each having a fixed line width equal to that
determined for Cr, resulting in a total area of IGABA*. IMM
represents the area under the metabolite-nulled (MM) peak
near 3.0 ppm multiplied by 1.29, the correction factor for
T1 relaxation. IMM was obtained using a constrained peak
fit where the line width was set equal to that of Cr plus
15 Hz. The corresponding experimentally measured value
of IMM was subtracted from IGABA* for each individual
scan. The factor 3/2 in Eq. [1] accounted for the different
number of protons in the Cr methyl vs. the -CH2 GABA
resonances. The Cr concentration, [Cr], was assumed to be
8 	mol/g (3). The editing efficiency, EffE, was 0.36, deter-
mined by comparing: (a) the unmodulated GABA signal
measured relative to glycine in short-echo stimulated-echo
acquisition mode (STEAM) spectra with (b) the edited
GABA signal measured relative to glycine in spectra of the
same voxel in the same phantom. Perfect editing for an
AX2 spin system would correspond to EffE  0.5. Signal
loss from T2 decay was assessed to be identical for GABA
and glycine in the phantom, and in vivo T2 of the Cr
methyl and of the -CH2 of GABA were assumed to be
identical. Given the approximate T1 of 1.5 s, as determined
from the metabolite-nulled experiment, potential differ-
ences in T1 have a negligible effect on the quantification at
the TR of 4.5 s.
RESULTS
The combination of VAPOR water suppression and
MEGA-editing resulted in a nearly absent water signal
(Fig. 1). The sensitivity improvement at 7 Tesla was ob-
served through detection of the H1 glucose resonance
(5.2 ppm) at 69 ms TE in an 8-mL volume (Fig. 1). In the
edited spectra (Fig. 2a), the absence of signal at 3.2 ppm,
the chemical shift of choline, suggests excellent subtrac-
tion accuracy. The flat baseline around 3.0 ppm, the ex-
cellent signal-to-noise ratio (SNR), and the narrow lines
resulted in excellent fits of the Cr and GABA resonances as
judged from the fit residuals (not shown). The chemical
shift of the GABA peak (3.01 ppm) was 0.02 ppm upfield
from Cr. The chemical shift of the MM peak (2.99 ppm)
was 7 Hz upfield from GABA at 7 Tesla. These offsets agree
FIG. 1. In vivo 1H NMR subspectrum in which the selective 180° MEGA pulse was set for water suppression only. TR  4.0 s, TE  69 ms,
NEX  128, VOI  8 mL. The glucose trace is vertically expanded from the subspectrum.
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with short TE spectra in rats (16), and spectra from dia-
lyzed rat brain cytosol (17). Glutamate, glutamine, and the
MM coherences at 0.9 ppm appeared in the edited spectra
(Fig. 2a) as a result of coupling partners within the band-
width of the editing pulses applied at 1.9 ppm. The NAA
signal at 2.0 ppm appears with opposite phase because
NAA is reduced when the editing pulse is applied at
1.9 ppm.
Complete elimination of the MM signal was not always
possible, as assessed in the edited metabolite-nulled spec-
tra (Fig. 2a, bottom trace). The residual contamination was
attributed to frequency drifts. While all volunteers were
instructed to lie still, the combination of respiration, head
motion, and static field drift frequently produced fre-
quency drifts that exceeded 5 Hz and resulted in measur-
able MM contamination.
Comparison of an in vivo spectrum expanded around
3.0 ppm to an accordingly line-broadened phantom spec-
trum (Fig. 2b) indicates the presence of a doublet whose
separation 
f was consistent with the majority of the signal
arising from GABA. In spectra of exceptional quality (i.e.,
where the subtraction error assessed from the residual
choline signal was less than 2%) the fit resulted in a
frequency separation, 
fin vivo, of 12.9  1.1 Hz (mean 
SD, N  8), which is somewhat lower than the 
f mea-
sured in the phantom (14 Hz) prior to line broadening. The
lower separation, 
fin vivo, was expected because of the
effect of broader line widths on the appearance of peak
separation in vivo.
The GABA concentration including MM contamination
was calculated based on Eq. [1] by setting IMM 
0 resulting in [GABA*]  0.88  0.23 	mol/g (mean  SD,
N  16). Conversely, the GABA concentration without
MM contamination was [GABA]  0.75  0.14 	mol/g
(mean  SD, N  16), corresponding to an edited GABA-
to-Cr signal ratio of 2.2  0.4% (mean  SD). Figure 3
illustrates the improved confidence when accounting for
MM contamination.
DISCUSSION
The proportion of MM contamination to total edited signal
GABA* was only 15%. While symmetric pulsing (11) at
7 Tesla did not completely remove MM contamination, it
did remove a substantial portion compared to the contam-
FIG. 2. a: Edited in vivo 1H NMR spectrum (top), and metabolite-nulled spectrum (bottom). TR  4.5 s, TE  69 ms, NEX  256, VOI 
27 mL, and TIR  0.975 s. b: Edited spectra expanded at 3.0 ppm in vivo (top) and accordingly line-broadened GABA phantom (bottom);
these two spectra were acquired using identical methods.
FIG. 3. Box plot of GABA concentrations (N  16) without subtract-
ing the MM contamination ([GABA*]) and after subtracting the MM
signal ([GABA]). The horizontal lines mark the 25th, 50th (median),
and 75th percentiles. The square indicates the mean, the error bars
the 5th and 95th percentiles, and the stars the outliers. Note the
more normally distributed values and smaller coefficient of variation
in the measurements after the MM signal is subtracted.
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ination of 34–44% assessed using other editing methods
(1,3). While the GABA concentration obtained without
MM contamination ([GABA]) is within 1 standard devia-
tion (SD) of that including MM contamination ([GABA*]),
the SD itself was reduced by a factor of 2 when MM
contamination was accounted for. The additional time re-
quired for measuring the metabolite-nulled spectrum re-
sulted in increased confidence in the GABA concentration
determined for each individual.
An advantage of difference editing methods over multi-
ple quantum methods is that the former retain singlet
resonances in the subspectra. In our study this advantage
allowed us to determine the overall phase of the spectrum,
which was used for individual phase correction, resulting
in improved spectral quality. This advantage also allowed
us to assess frequency drift, which is a detriment to all
methods designed to edit for GABA, including the fre-
quently used mathematical deconvolution of GABA and
MM (1,11). Because frequency may vary unpredictably
during each study, it appears to be advantageous to assess
MM contamination individually in an interleaved fashion.
Since the ratio of the area of the edited -CH2 GABA
resonance is only 2% of that of Cr, subtraction errors
greater than 2% may interfere with the measurement of
GABA concentration.
The GABA concentration determined in this study was
somewhat less than the previously reported 1.1 	mol/g (3)
and 1.3 	mol/g (1) measured in the same brain region
relative to 8 	mol/g Cr. However, most previous studies,
including our own study at 4 Tesla (2), neither discuss the
potential effects of frequency drifts on these calculations
nor report the constant detection of a resolved GABA
doublet. It is noteworthy that a recent study using the same
methodology reported similar low GABA concentrations
in nonhuman primates (11). Finally, a neurochemistry
textbook (18) states that GABA concentrations range from
0.8 to 2.3 	mol/g, which is based on chemical extraction.
Since GABA levels can rise in post-mortem tissue, it is not
surprising that the in vivo method described herein pro-
duced GABA levels that were at the lower end of what has
been reported in brain extracts.
However, the true GABA concentration may be even
lower, since homocarnosine, a dipeptide of GABA and
histidine, can coedit with GABA and may contribute as
much as 30% of the edited signal at 3.01 ppm (19). There-
fore, the GABA concentration may be as low as 0.5 	mol/g
in the human occipital lobe. This is in excellent agreement
with estimates from 13C NMR data, in which the GABA
signal was completely resolved (20).
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